Literature DB >> 9382401

The pathogenesis of venous limb gangrene associated with heparin-induced thrombocytopenia.

T E Warkentin1, L J Elavathil, C P Hayward, M A Johnston, J I Russett, J G Kelton.   

Abstract

BACKGROUND: Platelet-mediated arterial occlusion is a well-recognized cause of limb loss in patients with heparin-induced thrombocytopenia. However, the syndrome of distal ischemic necrosis complicating the deep venous thrombosis (venous limb gangrene) sometimes associated with heparin-induced thrombocytopenia has not been well characterized.
OBJECTIVE: To study the pathogenesis of venous limb gangrene associated with heparin-induced thrombocytopenia.
DESIGN: Characterization (based on descriptive and case-control studies) of a novel syndrome of limb loss and hypothesis testing by analysis of plasma samples.
SETTING: Five university-associated hospitals in one medical community. PATIENTS: Clinical and laboratory records of 158 patients with heparin-induced thrombocytopenia were reviewed to identify patients with venous limb gangrene (n = 8), limb arterial thrombosis (n = 10), and uncomplicated deep venous thrombosis (n = 58). MEASUREMENTS: Clinical and laboratory factors associated with venous limb gangrene, including thrombin-antithrombin complexes and vitamin K-dependent procoagulant and anticoagulant factors.
RESULTS: Warfarin treatment was more frequently associated with venous limb gangrene than with limb arterial thrombosis (8 of 8 patients compared with 3 of 10 patients; P = 0.004). The anticoagulant effect of warfarin seemed greater in the 8 patients with venous limb gangrene than in the 58 patients who did not develop gangrene (median International normalized ratio, 5.8 compared with 3.1; P < 0.001). Compared with plasma from controls, plasma from patients with venous limb gangrene had a higher ratio of thrombin-antithrombin complex to protein C activity during warfarin treatment. No hereditable abnormalities of the protein C anticoagulant pathway were seen in any patient.
CONCLUSIONS: Warfarin treatment of deep venous thrombosis associated with heparin-induced thrombocytopenia is a possible cause of venous limb gangrene, perhaps because of acquired failure of the protein C anticoagulant pathway to regulate thrombin generation.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9382401     DOI: 10.7326/0003-4819-127-9-199711010-00005

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  54 in total

Review 1.  Heparin-induced thrombocytopenia: patient profiles and clinical manifestations.

Authors:  F A Spencer
Journal:  J Thromb Thrombolysis       Date:  2000-11       Impact factor: 2.300

2.  Images in heparin-induced thrombocytopenia.

Authors:  O Ali
Journal:  J Thromb Thrombolysis       Date:  2000-11       Impact factor: 2.300

Review 3.  Laboratory testing for heparin-induced thrombocytopenia.

Authors:  T E Warkentin
Journal:  J Thromb Thrombolysis       Date:  2000-11       Impact factor: 2.300

Review 4.  Management of patients with heparin-induced thrombocytopenia: focus on recombinant hirudin.

Authors:  N Lubenow; A Greinacher
Journal:  J Thromb Thrombolysis       Date:  2000-11       Impact factor: 2.300

Review 5.  Laboratory diagnosis of heparin-induced thrombocytopenia and monitoring of alternative anticoagulants.

Authors:  Albrecht Leo; Susanne Winteroll
Journal:  Clin Diagn Lab Immunol       Date:  2003-09

6.  [Prevention of deep vein thrombosis in surgical departments].

Authors:  S Haas
Journal:  Chirurg       Date:  2004-03       Impact factor: 0.955

Review 7.  Unusual causes of cutaneous ulceration.

Authors:  Jaymie Panuncialman; Vincent Falanga
Journal:  Surg Clin North Am       Date:  2010-12       Impact factor: 2.741

Review 8.  Treatment and prevention of heparin-induced thrombocytopenia: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Lori-Ann Linkins; Antonio L Dans; Lisa K Moores; Robert Bona; Bruce L Davidson; Sam Schulman; Mark Crowther
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

Review 9.  Low molecular weight heparin-induced skin necrosis-a systematic review.

Authors:  A E Handschin; O Trentz; H J Kock; G A Wanner
Journal:  Langenbecks Arch Surg       Date:  2004-11-27       Impact factor: 3.445

10.  American Society of Hematology 2018 guidelines for management of venous thromboembolism: heparin-induced thrombocytopenia.

Authors:  Adam Cuker; Gowthami M Arepally; Beng H Chong; Douglas B Cines; Andreas Greinacher; Yves Gruel; Lori A Linkins; Stephen B Rodner; Sixten Selleng; Theodore E Warkentin; Ashleigh Wex; Reem A Mustafa; Rebecca L Morgan; Nancy Santesso
Journal:  Blood Adv       Date:  2018-11-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.